Evidence map›Paper›PMID 34164268›Full record

ArticleTranslational lung cancer research2021

M

Hui Chen, Xiao-Lin Ge, Zhao-Yue Zhang, Ming Liu, Rui-Yan Wu, Xiao-Fei Zhang, Li-Ping Xu, Hong-Yan Cheng, Xin-Chen Sun, Hong-Cheng Zhu

Open access · diamondAbstract read
In one paragraph

Article in Translational lung cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Narrative review of research progress of RNA mTranslational cancer research · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Frontiers in oncology · 2023
    Article
  14. Role of main RNA modifications in cancer: NSignal transduction and targeted therapy · 2022
    Review
  15. Biological roles of RNA mBiomarker research · 2022
    Review
  16. Article
  17. Article
  18. Article
  19. Analysis of mFrontiers in immunology · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Hui ChenDepartment of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xiao-Lin GeDepartment of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zhao-Yue ZhangDepartment of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Ming LiuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Rui-Yan WuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiao-Fei ZhangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Li-Ping XuDepartment of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Hong-Yan ChengDepartment of Synthetic Internal Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xin-Chen SunDepartment of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Hong-Cheng ZhuDepartment of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Nanjing Medical University · CNJiangsu Province Hospital · CNFudan University Shanghai Cancer Center · CNShanghai Institute of Hematology · CNShanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn recent years, immunotherapy has made great progress, and the regulatory role of epigenetics has been verified. However, the role of 5-methylcytosine (m

methodsBased on 11 m

resultsTwo m

conclusionsOur study revealed that m

Indexed as

immunotherapylung adenocarcinoma (LUAD)M5Ctumor microenvironment (TME)

Identifiers

PMID34164268
PMCPMC8182725
OpenAlexW3164394253

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.